Table 1. The characteristics of the participants.
| N(%) | |
|---|---|
| Benign breast disease | |
| Age (years) | |
| Median (Range) | 50 (47–53) |
| Menopausal status | |
| Postmenopausal | 125 (66.8) |
| Premenopausal | 62 (33.2) |
| Type | |
| adenosis | 30 (16.1) |
| Breast fibroadenoma | 106 (56.7) |
| intracanalicular papilloma | 38 (20.3) |
| Others | 13 (6.9) |
| Breast cancer | |
| Age (years) | |
| Median (Range) | 50 (42–56) |
| Menopausal status | |
| Postmenopausal | 123 (61.5) |
| Premenopausal | 77 (38.5) |
| Tumor size | |
| T1 | 168 (84.0) |
| T2 | 30 (15.0) |
| T3 | 2 (1.0) |
| Nodal status | |
| Positive | 2 (1.0) |
| negative | 198 (99.0) |
| Metastasis | |
| M0 | 200 (100.0) |
| M1 | 0 (0) |
| TNM stage | |
| I | 166 (83.0) |
| II | 33 (16.5) |
| III | 1 (0.5) |
| ER/PR | |
| +/+ | 113 (56.5) |
| +/− | 19 (9.5) |
| −/+ | 5 (2.5) |
| −/− | 63(31.5) |
| HER-2 | |
| Negative | 101 (50.5) |
| Positive | 99 (49.5) |
| Triple-negativity | |
| Triple-negative | 30 (15.0) |
| Non triple-negative | 170 (85.0) |
ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor-2.